ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib: A case report.
ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?
Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib.